Delayed
London S.E.
02:59:59 2024-04-30 am EDT
|
5-day change
|
1st Jan Change
|
1.6
GBX
|
0.00%
|
|
+3.23%
|
-65.96%
|
Fiscal Period: December |
2017
|
2018
|
2019
|
2020
|
2021
|
2022
|
---|
Capitalization
1 |
3.04
|
2.587
|
5.304
|
17.44
|
10.95
|
3.333
|
Enterprise Value (EV)
1 |
2.653
|
2.622
|
4.496
|
17.05
|
10.28
|
3.081
|
P/E ratio
|
-7.99
x
|
-2.64
x
|
-7.93
x
|
-21.1
x
|
-20.7
x
|
-6.52
x
|
Yield
|
-
|
-
|
-
|
-
|
-
|
-
|
Capitalization / Revenue
|
-
|
15,684,266
x
|
19,800,346
x
|
68,292,491
x
|
21,015,366
x
|
6,219,308
x
|
EV / Revenue
|
-
|
15,891,011
x
|
16,784,379
x
|
66,782,205
x
|
19,723,451
x
|
5,749,454
x
|
EV / EBITDA
|
-
|
-3,666,927
x
|
-9,423,577
x
|
-29,954,134
x
|
-28,798,060
x
|
-8,551,779
x
|
EV / FCF
|
-15.7
x
|
-6.14
x
|
-5.82
x
|
115
x
|
-59.4
x
|
-18.4
x
|
FCF Yield
|
-6.36%
|
-16.3%
|
-17.2%
|
0.87%
|
-1.68%
|
-5.43%
|
Price to Book
|
5.15
x
|
3.39
x
|
3.33
x
|
16.3
x
|
9.2
x
|
4.71
x
|
Nbr of stocks (in thousands)
|
67,559
|
120,346
|
134,275
|
170,108
|
182,508
|
182,621
|
Reference price
2 |
0.0450
|
0.0215
|
0.0395
|
0.1025
|
0.0600
|
0.0182
|
Announcement Date
|
4/30/18
|
4/30/19
|
5/4/20
|
4/20/21
|
4/28/22
|
4/25/23
|
Fiscal Period: December |
2017
|
2018
|
2019
|
2020
|
2021
|
2022
|
---|
Net sales
|
-
|
0.165
|
0.2679
|
0.2553
|
0.5211
|
0.5359
|
EBITDA
|
-
|
-0.7149
|
-0.4771
|
-0.5692
|
-0.3569
|
-0.3603
|
EBIT
1 |
-0.258
|
-0.7484
|
-0.5881
|
-0.6857
|
-0.4903
|
-0.5009
|
Operating Margin
|
-
|
-453.67%
|
-219.55%
|
-268.58%
|
-94.1%
|
-93.47%
|
Earnings before Tax (EBT)
1 |
-0.281
|
-0.7641
|
-0.6171
|
-0.7175
|
-0.5011
|
-0.5116
|
Net income
1 |
-0.281
|
-0.7641
|
-0.6387
|
-0.7175
|
-0.5011
|
-0.5116
|
Net margin
|
-
|
-463.16%
|
-238.42%
|
-281.04%
|
-96.16%
|
-95.47%
|
EPS
2 |
-0.005635
|
-0.008159
|
-0.004981
|
-0.004847
|
-0.002900
|
-0.002801
|
Free Cash Flow
1 |
-0.1686
|
-0.4273
|
-0.7729
|
0.1489
|
-0.173
|
-0.1673
|
FCF margin
|
-
|
-259.01%
|
-288.53%
|
58.31%
|
-33.21%
|
-31.23%
|
FCF Conversion (EBITDA)
|
-
|
-
|
-
|
-
|
-
|
-
|
FCF Conversion (Net income)
|
-
|
-
|
-
|
-
|
-
|
-
|
Dividend per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
4/30/18
|
4/30/19
|
5/4/20
|
4/20/21
|
4/28/22
|
4/25/23
|
Fiscal Period: December |
2017
|
2018
|
2019
|
2020
|
2021
|
2022
|
---|
Net Debt
1 |
-
|
0.03
|
-
|
-
|
-
|
-
|
Net Cash position
1 |
0.39
|
-
|
0.81
|
0.39
|
0.67
|
0.25
|
Leverage (Debt/EBITDA)
|
-
|
-0.0477
x
|
-
|
-
|
-
|
-
|
Free Cash Flow
1 |
-0.17
|
-0.43
|
-0.77
|
0.15
|
-0.17
|
-0.17
|
ROE (net income / shareholders' equity)
|
-90.9%
|
-113%
|
-50.9%
|
-52.5%
|
-44.3%
|
-53.9%
|
ROA (Net income/ Total Assets)
|
-41.7%
|
-54.7%
|
-25.5%
|
-26%
|
-20.3%
|
-22%
|
Assets
1 |
0.6735
|
1.397
|
2.508
|
2.764
|
2.466
|
2.33
|
Book Value Per Share
2 |
0.0100
|
0.0100
|
0.0100
|
0.0100
|
0.0100
|
0
|
Cash Flow per Share
2 |
0.0100
|
0
|
0.0100
|
0
|
0
|
0
|
Capex
|
-
|
-
|
0
|
-
|
0.01
|
0
|
Capex / Sales
|
-
|
-
|
1.52%
|
-
|
1.13%
|
0.28%
|
Announcement Date
|
4/30/18
|
4/30/19
|
5/4/20
|
4/20/21
|
4/28/22
|
4/25/23
|
|
1st Jan change
|
Capi.
|
---|
| -65.96% | 4.45M | | -16.55% | 8.43B | | +40.93% | 3.62B | | -35.59% | 2.61B | | -7.88% | 2.48B | | -8.06% | 2.34B | | -5.93% | 1.94B | | -18.96% | 1.56B | | -38.35% | 1.26B | | +6.91% | 1.1B |
Medical & Diagnostic Laboratories
|